Almost Half of Crohn's Disease Patients Achieved Endoscopic Response After One Year ff Maintenance Treatment with AbbVie's Risankizumab
AbbVie Inc (NYSE: ABBV) has announced positive top-line results from the Phase 3 maintenance study, FORTIFY, showing Skyrizi (risankizumab) achieved the co-primary endpoints of endoscopic response and clinical remission at one year in Crohn's disease.